For instance this led to trials of p110α inhibitors in cancers harbouring activating PIK3CA mutations or p110β inhibitors in tumours driven by PTEN loss, as this specific isoform was reported to be critical in this context [127,128,129,130,131]. This evidence concerns the gene PTEN and neoplasm.